Sermorelin Side Effects: What the Geref Label and Class Show
By DoseGauge Editorial · Updated 2026-06-13 · 7 min read
The side effects below come from the Geref (sermorelin acetate) label and from what the growth-hormone-secretagogue class indicates. Two limits frame everything here. First, the label's safety data describe the approved indication, growth hormone deficiency (largely studied in children), so they characterize that use, not adult anti-aging dosing. Second, current adult use is off-label and compounded, and long-term adult safety data are limited. With that said, the most common labeled reaction was an injection-site reaction, and the label lists a handful of less common effects (headache, flushing, dizziness, and others), alongside the growth-hormone-mediated concerns the class carries. This page is informational and educational only, not medical advice, and it does not recommend sermorelin or any dose. For background on the compound itself, see what sermorelin is.
What the Geref label lists
The clearest documented side-effect picture for sermorelin comes from the Geref (sermorelin acetate) prescribing information, as referenced by RxList. That label describes the safety experience from the approved indication, growth hormone deficiency, and it is the right place to start because it is an agency-reviewed document rather than anecdote.
The most common reaction by a wide margin was local. The label reports a local injection reaction characterized by pain, swelling, or redness, occurring in roughly 1 in 6 patients, which made it the most frequent treatment-related event. The label notes that a small number of patients discontinued because of these injection reactions. Because sermorelin is given by subcutaneous injection, this is the kind of reaction the route of administration would predict.
Beyond the injection site, the label lists several less common reactions, each reported at less than 1%: headache, flushing, dysphagia (difficulty swallowing), dizziness, hyperactivity, somnolence (sleepiness), and urticaria (hives). Separately, in the context of using sermorelin intravenously as a diagnostic agent, the label notes reactions including flushing of the face, nausea, headache, vomiting, dysgeusia (taste changes), pallor, and tightness in the chest. The label also reports that the incidence of hypothyroidism during sermorelin therapy was 6.5%.
Two things are worth stating plainly. First, this is the label's list, drawn from the studied population for the approved indication, not a modern adult adverse-event table. Second, the figures here (the roughly 1-in-6 injection-site rate and the 6.5% hypothyroidism incidence) are the label's own reported numbers; the less common reactions are described qualitatively because the label characterizes them as occurring below 1% rather than at a single fixed rate. This page does not assign frequencies the label does not state.
Growth-hormone-mediated effects
Sermorelin works by stimulating the pituitary to release the body's own growth hormone, which in turn raises IGF-1. That mechanism is the source of a second category of effects, the ones tied to the growth-hormone-secretagogue class rather than to any single labeled reaction.
Raising growth hormone and IGF-1 is associated with recognized class effects. The two most often discussed are fluid retention (which can present as swelling, joint discomfort, or carpal-tunnel-type symptoms) and effects on glucose tolerance and insulin sensitivity, because growth hormone influences how the body handles blood sugar. These are class-level, qualitative considerations: they describe the kind of effect that raising growth hormone and IGF-1 can carry, not a documented rate for sermorelin specifically. They are part of why growth-hormone-pathway drugs warrant clinical oversight, including for anyone with a glucose or thyroid condition, rather than something this page can quantify.
Off-label adult use and what the label does not cover
Everything in the labeled list above comes from the approved indication: growth hormone deficiency, with the safety experience drawn largely from that population and from the historical trials behind the product. Geref was approved for growth promotion in children with growth hormone deficiency and for diagnostic pituitary testing, and was discontinued commercially in 2008 for business reasons unrelated to safety or efficacy. Adult anti-aging or wellness use was never an approved indication.
That history matters for how the label's safety data transfer. Current adult use of sermorelin, for anti-aging or wellness goals, is off-label and supplied through compounding pharmacies, at doses and in a population the label did not study. So the documented reactions, their frequencies, and the monitoring context were established for a different use, and they may not transfer to adult off-label dosing in the same way. Just as important, there are no large, long-term adult safety studies of sermorelin used this way. The absence of that data is not reassurance; it means uncommon or delayed effects in adults using it off-label are simply not well characterized. This page cannot fill that gap, and it does not try to.
When to talk to a clinician
Because this page summarizes a label and a drug class rather than assessing any individual, the practical takeaway is to route the decision to someone who can. A licensed clinician can weigh personal history (including any thyroid, glucose, or pituitary condition), review the growth-hormone-mediated concerns, and account for the fact that current adult use is off-label and not covered by a current finished-product label. Anything that feels like an allergic reaction, persistent or severe injection-site reactions, or new symptoms after starting are reasons to contact a clinician promptly. DoseGauge does not recommend sermorelin, any dose, or any provider; it performs reconstitution and unit math on the values you enter and makes no judgment about whether a compound is appropriate for you.
CalculatorOpen the Sermorelin dosage calculator ->Frequently asked questions
What are the most common sermorelin side effects?
Per the Geref (sermorelin acetate) label, the most common adverse reaction was a local injection-site reaction (pain, swelling, or redness), reported in roughly 1 in 6 patients. The label also lists less common reactions, each below 1%: headache, flushing, dysphagia, dizziness, hyperactivity, somnolence, and urticaria. Those figures come from the approved growth-hormone-deficiency indication, not from a modern adult adverse-event table, and the page does not assign frequencies the label does not state.
Is sermorelin safe?
This page cannot simply call it safe. The Geref label and its underlying trials inform safety for the approved indication, growth hormone deficiency studied largely in children, but they do not characterize current adult off-label use. There are no large, long-term adult safety studies of sermorelin used for anti-aging or wellness, and there is no currently approved finished sermorelin product, so the adult risk picture is not well characterized. That is different from saying the risks are low. A safety question about a specific person is a clinical question for a licensed clinician.
Does sermorelin affect blood sugar?
Possibly, because of how it works. Sermorelin raises the body's own growth hormone and, downstream, IGF-1, and effects on glucose tolerance and insulin sensitivity are a recognized growth-hormone-mediated class concern. There is no current adult label quantifying this for sermorelin, so it cannot be stated as a documented rate, but it is one reason these drugs warrant clinical oversight. Discuss blood-sugar effects with a licensed clinician, especially if you have any glucose or insulin condition.
Are sermorelin side effects different for off-label use?
The label's documented reactions and frequencies come from the approved growth-hormone-deficiency indication, studied largely in children, not from adult anti-aging dosing. Current adult use is off-label and compounded, in a different population and often at different doses, so the documented profile may not transfer in the same way, and long-term adult safety data are limited. A licensed clinician is the right person to weigh that.
Informational and educational only. Not medical advice. DoseGauge computes from the values you enter and does not recommend a dose. Talk to a licensed clinician before using any peptide or GLP-1 medication.